American milk isn’t sold in the European Union primarily because of a synthetic growth hormone called recombinant bovine somatotropin (rbST), which is approved for use in U.S. dairy farming but has been banned in the EU since 1999. The ban reflects a fundamental difference in how the two regions weigh health risks, animal welfare, and food safety standards. Beyond the hormone issue, the EU also enforces stricter limits on the amount of white blood cells allowed in milk, a measure of udder health and overall milk quality.
The Growth Hormone at the Center of the Ban
RbST is a lab-made version of a hormone cows naturally produce to regulate milk production. When injected into dairy cows, it boosts milk output significantly. The U.S. Food and Drug Administration approved it in 1993, concluding that milk from treated cows was safe for humans. The European Union took a different path. European regulators initially raised concerns about potential human health risks, including the possibility that hormone-treated milk could increase cancer risk. By December 1999, the EU formally prohibited rbST, though the final decision rested primarily on animal welfare grounds after European scientific committees found insufficient evidence of direct harm to humans.
That distinction matters. The EU didn’t just ban the hormone from being used on European farms. It also blocked imports of dairy products from cows treated with it, which effectively shut out a significant portion of American milk.
What the Hormone Does to Cows
The animal welfare case against rbST is backed by substantial data. A major meta-analysis published in the Canadian Journal of Veterinary Research found that cows treated with rbST had a 25% higher risk of developing mastitis, a painful bacterial infection of the udder. Lameness risk increased by roughly 55%. And treated cows were about 40% more likely to fail to conceive, creating serious reproductive problems in herds.
Mastitis is particularly relevant to the milk quality debate because it’s typically treated with antibiotics, raising concerns about antibiotic residues ending up in the milk supply. While both the U.S. and EU test for antibiotic residues and discard contaminated milk, European regulators viewed the increased mastitis rate as an unacceptable side effect that put more pressure on the system overall.
The IGF-1 Question
The human health concern that drew the most attention involves a protein called insulin-like growth factor 1 (IGF-1). Cows treated with rbST produce milk with higher levels of IGF-1, and some researchers have raised questions about whether elevated IGF-1 intake could be linked to increased cancer risk in humans. IGF-1 is not broken down by pasteurization or by stomach acid, meaning it survives intact through processing and digestion.
The science here is genuinely unsettled. U.S. regulators have maintained that the IGF-1 increase is too small to pose a meaningful health risk, while European authorities took a more cautious stance. This reflects a broader philosophical difference: the EU tends to restrict substances until they’re proven safe (the precautionary principle), while U.S. regulation generally permits substances unless they’re proven harmful.
Stricter Standards for Milk Quality
Even setting the hormone issue aside, American milk faces another barrier to the European market: somatic cell count limits. Somatic cells are white blood cells that show up in milk, and higher counts generally indicate infection or inflammation in the cow’s udder. They serve as a proxy for overall herd health and milk quality.
The EU caps somatic cell counts at 400,000 cells per milliliter. The U.S. limit is nearly double that, at 750,000 cells per milliliter. According to the USDA, American milk that exceeds the 400,000 threshold cannot be certified for export to the EU without a special exemption. This means that milk considered perfectly legal for sale in the United States can be too high in somatic cells to meet European standards.
How Common Is rbST Use Today?
Here’s an irony: the hormone that triggered the ban has largely fallen out of favor in the U.S. anyway. In 2000, about 35% of American milk came from farms using rbST. By 2021, that figure had dropped to just 2%, according to USDA data. Consumer demand drove much of this shift. Major retailers and dairy brands moved to “rbST-free” sourcing as shoppers increasingly sought it out.
The FDA’s position on labeling reflects its view that there’s no meaningful difference between treated and untreated milk. Companies can label their products as coming “from cows not treated with rbST,” but the FDA requires them to include a disclaimer stating that no significant difference has been shown between milk from treated and untreated cows. The agency won’t even allow the phrase “rbST-free” because all milk naturally contains some amount of the base hormone.
Why the Ban Still Stands
Even with rbST use plummeting in the U.S., the European ban remains in place. This is partly structural: the EU ban covers the substance itself, not just its prevalence, so it would need to be formally repealed through regulatory channels. But the somatic cell count difference also persists, and the broader regulatory philosophies of the two regions haven’t converged. The EU continues to apply the precautionary principle to food additives and production methods, while the U.S. maintains its existing approval framework.
For American dairy producers who want to export to Europe, the path exists but is narrow. They must certify that their milk meets the EU’s somatic cell count threshold and comply with other European food safety requirements. The volume of U.S. dairy exports to the EU remains small compared to domestic sales, partly because meeting those standards adds cost and complexity that most producers don’t find worthwhile.